Search

Your search keyword '"Itoh, Kyogo"' showing total 1,034 results
Start Over Author "Itoh, Kyogo"
1,034 results on '"Itoh, Kyogo"'

151. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer

Author

Yoshimura, Kazuhiro, primary, Minami, Takafumi, additional, Nozawa, Masahiro, additional, Kimura, Takahiro, additional, Egawa, Shin, additional, Fujimoto, Hiroyuki, additional, Yamada, Akira, additional, Itoh, Kyogo, additional, and Uemura, Hirotsugu, additional

Published
2016
Full Text
View/download PDF

152. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients

Author

Iwasa, Satoru, primary, Yamada, Yasuhide, additional, Heike, Yuji, additional, Shoji, Hirokazu, additional, Honma, Yoshitaka, additional, Komatsu, Nobukazu, additional, Matsueda, Satoko, additional, Yamada, Akira, additional, Morita, Michi, additional, Yamaguchi, Rin, additional, Tanaka, Natsuki, additional, Kawahara, Akihiko, additional, Kage, Masayoshi, additional, Shichijo, Shigeki, additional, Sasada, Tetsuro, additional, and Itoh, Kyogo, additional

Published
2016
Full Text
View/download PDF

153. Personalized immunotherapy in colorectal cancer

Author

Ohtake, Junya, primary, Wada, Satoshi, additional, Yada, Erika, additional, Fujimoto, Yuki, additional, Uchiyama, Hidemi, additional, Yoshida, Shintaro, additional, Itoh, Kyogo, additional, and Sasada, Tetsuro, additional

Published
2016
Full Text
View/download PDF

156. Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer

Author

Muroya, Daisuke, primary, Yutani, Shigeru, additional, Shichijo, Shigeki, additional, Yamada, Akira, additional, Sakamoto, Shinjiro, additional, Naito, Masayasu, additional, Okuda, Koji, additional, Morita, Michi, additional, Yamaguchi, Rin, additional, and Itoh, Kyogo, additional

Published
2016
Full Text
View/download PDF

157. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Author

Takayama, Koichi, primary, Sugawara, Shunichi, additional, Saijo, Yasuo, additional, Maemondo, Makoto, additional, Sato, Atsushi, additional, Takamori, Shinzo, additional, Harada, Taishi, additional, Sasada, Tetsuro, additional, Kakuma, Tatsuyuki, additional, Kishimoto, Junji, additional, Yamada, Akira, additional, Noguchi, Masanori, additional, Itoh, Kyogo, additional, and Nakanishi, Yoichi, additional

Published
2016
Full Text
View/download PDF

158. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

Author

Noguchi, Masanori, primary, Matsumoto, Kazumasa, additional, Uemura, Hirotsugu, additional, Arai, Gaku, additional, Eto, Masatoshi, additional, Naito, Seiji, additional, Ohyama, Chikara, additional, Nasu, Yasutomo, additional, Tanaka, Masatoshi, additional, Moriya, Fukuko, additional, Suekane, Shigetaka, additional, Matsueda, Satoko, additional, Komatsu, Nobukazu, additional, Sasada, Tetsuro, additional, Yamada, Akira, additional, Kakuma, Tatsuyuki, additional, and Itoh, Kyogo, additional

Published
2016
Full Text
View/download PDF

159. Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

Author

Sakamoto, Shinjiro, Yoshitomi, Munehiro, Yutani, Shigeru, Terazaki, Yasuhiro, Yoshiyama, Koichi, Ioji, Tetsuya, Matsueda, Satoko, Yamada, Akira, Takamori, Shinzo, Itoh, Kyogo, Hattori, Noboru, Kohno, Nobuoki, Sasada, Tetsuro, Sakamoto, Shinjiro, Yoshitomi, Munehiro, Yutani, Shigeru, Terazaki, Yasuhiro, Yoshiyama, Koichi, Ioji, Tetsuya, Matsueda, Satoko, Yamada, Akira, Takamori, Shinzo, Itoh, Kyogo, Hattori, Noboru, Kohno, Nobuoki, and Sasada, Tetsuro

Abstract

Since cancer vaccines do not always elicit beneficial effects in treated patients, identification of biomarkers for predicting clinical outcomes would be highly desirable. We previously reported that abnormal granulocytes present in peripheral blood mononuclear cells (PBMC) may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination (PPV). In the current study, we examined whether soluble factors derived from granulocytes, such as matrix metalloproteinase 9 (MMP-9), myeloperoxidase (MPO), and arginase 1 (ARG1), and inhibitory cytokine TGFβ in pre-vaccination plasma were useful for predicting prognosis after PPV in advanced cancer patients. In biliary tract cancer (n=25), multivariate Cox regression analysis demonstrated that patients with higher plasma MMP-9 levels had a significantly worse overall survival (OS) [hazard ratio (HR) = 4.637, 95% confidence interval (CI) = 1.670 - 12.877, P = 0.003], whereas MPO, ARG1, or TGFβ levels were not correlated with OS. Similarly, patients with higher MMP-9 levels showed worse prognosis than those with lower MMP-9 levels in other types of advanced cancers, including non-small cell lung cancer (n=32, P = 0.037 by log-rank test), and pancreatic cancer (n=41, P = 0.042 by log-rank test). Taken together, plasma MMP-9 levels before vaccination might be potentially useful as a biomarker for selecting advanced cancer patients who would benefit from PPV., This study was supported by a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan; a research program of the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan; and Kurozumi Medical Foundation.

Published
2015

160. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele

Author

Sakamoto, Shinjiro, Matsueda, Satoko, Takamori, Shinzo, Toh, Uhi, Noguchi, Masanori, Yutani, Shigeru, Yamada, Akira, Shichijo, Shigeki, Yamada, Teppei, Suekane, Shigetaka, Kawano, Kouichiro, Sasada, Tetsuro, Hattori, Noboru, Kohno, Nobuoki, Itoh, Kyogo, Sakamoto, Shinjiro, Matsueda, Satoko, Takamori, Shinzo, Toh, Uhi, Noguchi, Masanori, Yutani, Shigeru, Yamada, Akira, Shichijo, Shigeki, Yamada, Teppei, Suekane, Shigetaka, Kawano, Kouichiro, Sasada, Tetsuro, Hattori, Noboru, Kohno, Nobuoki, and Itoh, Kyogo

Abstract

type:text, To develop a peptide vaccine for cancer patients with the HLA-A26 allele, which is a minor population worldwide, we investigated the immunological responses of HLA-A26+ ⁄ A26+ cancer patients to four different CTL epitope peptides under personalized peptide vaccine regimens. In personalized peptide vaccine regimens, two to four peptides showing positive peptide-specific IgG responses in pre-vaccination plasma were selected from the four peptide candidates applicable for HLA-A26+ ⁄ A26+ cancer patients and administered s.c. Peptide-specific CTL and IgG responses along with cytokine levels were measured before and after vaccination. Cell surface markers in PBMCs and plasma cytokine levels were also measured. In this study, 21 advanced cancer patients, including seven lung, three breast, two pancreas, and two colon cancer patients, were enrolled. Their HLAA26 genotypes were HLA-A26:01 (n = 24), HLA-A26:03 (n = 10), and HLA-A26:02 (n = 8). One, 14, and 6 patients received two, three, and four peptides, respectively. Grade 1 or 2 skin reactions at the injection sites were observed in the majority of patients, but no severe adverse events related to the vaccination were observed. Peptide-specific CTL responses were augmented in 39% or 22% of patients after one or two cycles of vaccination, respectively. Notably, peptide-specific IgG were augmented in 63% or 100% of patients after one or two cycles of vaccination, respectively. Personalized peptide vaccines with these four CTL epitope peptides could be feasible for HLA-A26+ advanced cancer patients because of their safety and higher rates of immunological responses., This study was supported in part by the Japan Agency for Medical Research and development, AMED, a research program of the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a grant from the Sendai Kousei Hospital.

Published
2015

165. Immunological evaluation of peptide vaccination for cancer patients with the HLA‐A26 allele

Author

Sakamoto, Shinjiro, primary, Matsueda, Satoko, additional, Takamori, Shinzo, additional, Toh, Uhi, additional, Noguchi, Masanori, additional, Yutani, Shigeru, additional, Yamada, Akira, additional, Shichijo, Shigeki, additional, Yamada, Teppei, additional, Suekane, Shigetaka, additional, Kawano, Kouichiro, additional, Sasada, Tetsuro, additional, Hattori, Noboru, additional, Kohno, Nobuoki, additional, and Itoh, Kyogo, additional

Published
2015
Full Text
View/download PDF

166. Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

Author

Sakamoto, Shinjiro, primary, Yoshitomi, Munehiro, additional, Yutani, Shigeru, additional, Terazaki, Yasuhiro, additional, Yoshiyama, Koichi, additional, Ioji, Tetsuya, additional, Matsueda, Satoko, additional, Yamada, Akira, additional, Takamori, Shinzo, additional, Itoh, Kyogo, additional, Hattori, Noboru, additional, Kohno, Nobuoki, additional, and Sasada, Tetsuro, additional

Published
2015
Full Text
View/download PDF

167. Randomized phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients previously treated for advanced wild-type EGFR non-small-cell lung cancer.

Author

Sugawara, Shunichi, primary, Takayama, Koichi, additional, Sato, Atsushi, additional, Maemondo, Makoto, additional, Takamori, Shinzo, additional, Sasada, Tetsuro, additional, Kakuma, Tatsuyuki, additional, Kishimoto, Junji, additional, Yamada, Akira, additional, Noguchi, Masanori, additional, Itoh, Kyogo, additional, and Nakanishi, Yoichi, additional

Published
2015
Full Text
View/download PDF

170. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine

Author

NARITA, MIWAKO, primary, KANDA, TATSUO, additional, ABE, TAKASHI, additional, UCHIYAMA, TAKAYOSHI, additional, IWAFUCHI, MINAMI, additional, ZHENG, ZHIYIN, additional, LIU, AICHUN, additional, KAIFU, TSUTOMU, additional, KOSUGI, SHINICHI, additional, MINAGAWA, MASAHIRO, additional, ITOH, KYOGO, additional, and TAKAHASHI, MASUHIRO, additional

Published
2015
Full Text
View/download PDF

171. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Author

Yutani, Shigeru, primary, Ueshima, Kazuomi, additional, Abe, Kazumichi, additional, Ishiguro, Atsushi, additional, Eguchi, Junichi, additional, Matsueda, Satoko, additional, Komatsu, Nobukazu, additional, Shichijo, Shigeki, additional, Yamada, Akira, additional, Itoh, Kyogo, additional, Sasada, Tetsuro, additional, Kudo, Masatoshi, additional, and Noguchi, Masanori, additional

Published
2015
Full Text
View/download PDF

172. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.

Author

Sakamoto, Shinjiro, Matsueda, Satoko, Takamori, Shinzo, Toh, Uhi, Noguchi, Masanori, Yutani, Shigeru, Yamada, Akira, Shichijo, Shigeki, Yamada, Teppei, Suekane, Shigetaka, Kawano, Kouichiro, Naitou, Masayasu, Sasada, Tetsuro, Hattori, Noboru, Kohno, Nobuoki, and Itoh, Kyogo

Abstract

The HLA-A11 or -A33 allele is found in approximately 18% or 10% of the Asian population, respectively, but each of which is a minor allele worldwide, and therefore no clinical trials were previously conducted. To develop a therapeutic peptide vaccine for each of them, we investigated immunological responses of advanced cancer patients with the HLA-A11+/A11+ ( n = 18) or -A33+/A33+ ( n = 13) allele to personalized peptide vaccine ( PPV) regimens. The primary sites of HLA-A11+/A11+ or -A33+/A33+ patients were the colon ( n = 4 or 2), stomach (2 or 3), breast (3 or 2), lung and pancreas (2 or 2), and so on. For PPV, a maximum of four peptides were selected from nine different peptides capable of binding to HLA-A11 and -A33 molecules based on the pre-existing peptide-specific IgG responses. There were no severe adverse events related to PPV. At the end of the first cycle, peptide-specific CTL responses were augmented in 4/12 or 2/9 of HLA-A11+/A11+ or -A33+/A33+ patients, while peptide-specific IgG responses were augmented in 6/14 or 4/10 patients, respectively. Clinical responses consisted of four stable diseases and 14 progressive diseases in HLA-A11+/A11+patients, versus seven and six in -A33+/A33+patients, respectively. Further clinical study of PPV could be recommended because of the safety and positive immunological responses. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

173. Effect of recombinant erythropoietin on peripheral T lymphocytes

Author

Hisatomi, Kouichi, Nakao, Masanobu, Isomura, Tadashi, Kosuga, Kenichi, and Itoh, Kyogo

Subjects
Glycoproteins, T cells, Growth factors, Erythropoietin, Recombinant, Health
Abstract

Byline: Kouichi Hisatomi, Masanobu Nakao, Tadashi Isomura, Kenichi Kosuga, Kyogo Itoh Author Affiliation: Fukuoka, Japan Article Note: (footnote) [star] From the Second Department of Surgerya and the Department of Immunology,b Kurume University School of Medicine, Fukuoka, Japan., [star][star] J THORAC CARDIOVASC SURG 1995;109:809, a 0022-5223/95 $3.00 + 0, aa 12/8/57781

Published
1995

175. Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, additional, Motoyama, Satoru, additional, Nomura, Takanobu, additional, Tanaka, Natsuki, additional, Kawahara, Akihiko, additional, Yamaguchi, Tomohiko, additional, Matsueda, Satoko, additional, Komatsu, Nobukazu, additional, Miura, Masatomo, additional, Hinai, Yudai, additional, Hattori, Satoshi, additional, Yamada, Akira, additional, Kage, Masayoshi, additional, Itoh, Kyogo, additional, Akagi, Yoshito, additional, and Sasada, Tetsuro, additional

Published
2014
Full Text
View/download PDF

176. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens

Author

YAMADA, TEPPEI, primary, TERAZAKI, YASUHIRO, additional, SAKAMOTO, SHINJIRO, additional, YOSHIYAMA, KOICHI, additional, MATSUEDA, SATOKO, additional, KOMATSU, NOBUKAZU, additional, WAKI, KAYOKO, additional, YAMADA, AKIRA, additional, KAWAHARA, AKIHIKO, additional, KAGE, MASAYOSHI, additional, SUGAWARA, SHUNICHI, additional, YAMASHITA, YUICHI, additional, SASADA, TETSURO, additional, TAKAMORI, SHINZO, additional, and ITOH, KYOGO, additional

Published
2014
Full Text
View/download PDF

177. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Author

Takahashi, Ryuji, primary, Toh, Uhi, additional, Iwakuma, Nobutaka, additional, Takenaka, Miki, additional, Otsuka, Hiroko, additional, Furukawa, Mina, additional, Fujii, Teruhiko, additional, Seki, Naoko, additional, Kawahara, Akihiko, additional, Kage, Masayoshi, additional, Matsueda, Satoko, additional, Akagi, Yoshito, additional, Yamada, Akira, additional, Itoh, Kyogo, additional, and Sasada, Tetsuro, additional

Published
2014
Full Text
View/download PDF

178. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients previously treated with two or more chemotherapy regimens.

Author

Sugawara, Shunichi, primary, Yamada, Teppei, additional, Matsueda, Satoko, additional, Yoshiyama, Koichi, additional, Sakamoto, Shinjiro, additional, Ishimoto, Osamu, additional, Komatsu, Nobukazu, additional, Yamada, Akira, additional, Takamori, Shinzo, additional, Sasada, Tetsuro, additional, and Itoh, Kyogo, additional

Published
2014
Full Text
View/download PDF

179. Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for breast cancer patients in the adjuvant setting.

Author

Toh, Uhi, primary, Iwakuma, Nobutaka, additional, Mishima, Mai, additional, Takenaka, Miki, additional, Takahashi, Ryuji, additional, Furukawa, Mina, additional, Fujii, Teruhiko, additional, Ogo, Etsuyo, additional, Nakagawa, Shino, additional, Tanaka, Maki, additional, Sasada, Tetsuro, additional, Itoh, Kyogo, additional, and Akagi, Yoshito, additional

Published
2014
Full Text
View/download PDF

181. Randomized phase II study of personalized peptide vaccination in patients with advanced bladder cancer progressing after chemotherapy.

Author

Noguchi, Masanori, primary, Matsumoto, Kazumasa, additional, Uemura, Hirotsugu, additional, Arai, Gaku, additional, Eto, Masatoshi, additional, Naito, Seiji, additional, Ohyama, Chikara, additional, Nasu, Yasutomo, additional, Tanaka, Masatoshi, additional, Moriya, Fukuko, additional, Suekane, Shigetaka, additional, Matsueda, Satoko, additional, Komatsu, Nobukazu, additional, Sasada, Tetsuro, additional, Yamada, Akira, additional, and Itoh, Kyogo, additional

Published
2014
Full Text
View/download PDF

186. Cancer classification using the Immunoscore : a worldwide task force

Author

Galon, Jerome, Pages, Franck, Marincola, Francesco M., Angell, Helen K., Thurin, Magdalena, Lugli, Alessandro, Zlobec, Inti, Berger, Anne, Bifulco, Carlo, Botti, Gerardo, Tatangelo, Fabiana, Britten, Cedrik M., Kreiter, Sebastian, Chouchane, Lotfi, Delrio, Paolo, Arndt, Hartmann, Asslaber, Martin, Maio, Michele, Masucci, Giuseppe V., Mihm, Martin, Vidal-Vanaclocha, Fernando, Allison, James P., Gnjatic, Sacha, Hakansson, Leif, Huber, Christoph, Singh-Jasuja, Harpreet, Ottensmeier, Christian, Zwierzina, Heinz, Laghi, Luigi, Grizzi, Fabio, Ohashi, Pamela S., Shaw, Patricia A., Clarke, Blaise A., Wouters, Bradly G., Kawakami, Yutaka, Hazama, Shoichi, Okuno, Kiyotaka, Wang, Ena, O'Donnell-Tormey, Jill, Lagorce, Christine, Pawelec, Graham, Nishimura, Michael I., Hawkins, Robert, Lapointe, Rejean, Lundqvist, Andreas, Khleif, Samir N., Ogino, Shuji, Gibbs, Peter, Waring, Paul, Sato, Noriyuki, Torigoe, Toshihiko, Itoh, Kyogo, Patel, Prabhu S., Shukla, Shilin N., Palmqvist, Richard, Nagtegaal, Iris D., Wang, Yili, D'Arrigo, Corrado, Kopetz, Scott, Sinicrope, Frank A., Trinchieri, Giorgio, Gajewski, Thomas F., Ascierto, Paolo A., Fox, Bernard A., Galon, Jerome, Pages, Franck, Marincola, Francesco M., Angell, Helen K., Thurin, Magdalena, Lugli, Alessandro, Zlobec, Inti, Berger, Anne, Bifulco, Carlo, Botti, Gerardo, Tatangelo, Fabiana, Britten, Cedrik M., Kreiter, Sebastian, Chouchane, Lotfi, Delrio, Paolo, Arndt, Hartmann, Asslaber, Martin, Maio, Michele, Masucci, Giuseppe V., Mihm, Martin, Vidal-Vanaclocha, Fernando, Allison, James P., Gnjatic, Sacha, Hakansson, Leif, Huber, Christoph, Singh-Jasuja, Harpreet, Ottensmeier, Christian, Zwierzina, Heinz, Laghi, Luigi, Grizzi, Fabio, Ohashi, Pamela S., Shaw, Patricia A., Clarke, Blaise A., Wouters, Bradly G., Kawakami, Yutaka, Hazama, Shoichi, Okuno, Kiyotaka, Wang, Ena, O'Donnell-Tormey, Jill, Lagorce, Christine, Pawelec, Graham, Nishimura, Michael I., Hawkins, Robert, Lapointe, Rejean, Lundqvist, Andreas, Khleif, Samir N., Ogino, Shuji, Gibbs, Peter, Waring, Paul, Sato, Noriyuki, Torigoe, Toshihiko, Itoh, Kyogo, Patel, Prabhu S., Shukla, Shilin N., Palmqvist, Richard, Nagtegaal, Iris D., Wang, Yili, D'Arrigo, Corrado, Kopetz, Scott, Sinicrope, Frank A., Trinchieri, Giorgio, Gajewski, Thomas F., Ascierto, Paolo A., and Fox, Bernard A.

Abstract

Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the ` Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J T

Published
2012
Full Text
View/download PDF

187. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

Author

Galon, Jérôme, primary, Mlecnik, Bernhard, additional, Bindea, Gabriela, additional, Angell, Helen K, additional, Berger, Anne, additional, Lagorce, Christine, additional, Lugli, Alessandro, additional, Zlobec, Inti, additional, Hartmann, Arndt, additional, Bifulco, Carlo, additional, Nagtegaal, Iris D, additional, Palmqvist, Richard, additional, Masucci, Giuseppe V, additional, Botti, Gerardo, additional, Tatangelo, Fabiana, additional, Delrio, Paolo, additional, Maio, Michele, additional, Laghi, Luigi, additional, Grizzi, Fabio, additional, Asslaber, Martin, additional, D'Arrigo, Corrado, additional, Vidal‐Vanaclocha, Fernando, additional, Zavadova, Eva, additional, Chouchane, Lotfi, additional, Ohashi, Pamela S, additional, Hafezi‐Bakhtiari, Sara, additional, Wouters, Bradly G, additional, Roehrl, Michael, additional, Nguyen, Linh, additional, Kawakami, Yutaka, additional, Hazama, Shoichi, additional, Okuno, Kiyotaka, additional, Ogino, Shuji, additional, Gibbs, Peter, additional, Waring, Paul, additional, Sato, Noriyuki, additional, Torigoe, Toshihiko, additional, Itoh, Kyogo, additional, Patel, Prabhu S, additional, Shukla, Shilin N, additional, Wang, Yili, additional, Kopetz, Scott, additional, Sinicrope, Frank A, additional, Scripcariu, Viorel, additional, Ascierto, Paolo A, additional, Marincola, Francesco M, additional, Fox, Bernard A, additional, and Pagès, Franck, additional

Published
2013
Full Text
View/download PDF

189. EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation

Author

Yamada, Teppei, primary, Azuma, Koichi, additional, Muta, Emi, additional, Kim, Jintaek, additional, Sugawara, Shunichi, additional, Zhang, Guang Lan, additional, Matsueda, Satoko, additional, Kasama-Kawaguchi, Yuri, additional, Yamashita, Yuichi, additional, Yamashita, Takuto, additional, Nishio, Kazuto, additional, Itoh, Kyogo, additional, Hoshino, Tomoaki, additional, and Sasada, Tetsuro, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results